Pulse Biosciences Enhances Leadership to Advance Electrophysiology Innovations and Treatments

Pulse Biosciences Fortifies Leadership to Accelerate Electrophysiology Innovations

Pulse Biosciences, Inc. strengthens its clinical leadership team with the recent appointment of Dr. David Kenigsberg as Chief Medical Officer of Electrophysiology. Dr. Kenigsberg, a distinguished cardiac electrophysiologist and founder of Florida Heart Rhythm Specialists, brings extensive experience to Pulse, particularly in the realm of atrial fibrillation (AF) treatment. His role is pivotal as the company pushes forward with its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, which has shown promising results in rapidly isolating pulmonary veins. The addition of Dr. Kenigsberg to the executive team signals Pulse’s commitment to enhancing its innovative solutions in the electrophysiology space.

Alongside Dr. Kenigsberg, Dr. Andrea Natale, a prominent figure in cardiac arrhythmia treatment and Executive Medical Director of the Texas Cardiac Arrhythmia Institute, joins as a medical advisor. Dr. Natale’s profound expertise, including participation in numerous first-in-human trials, positions him to significantly influence the clinical development of Pulse's technologies. The advisory board also encompasses Dr. Vivek Reddy and Dr. Jacob Koruth, who collectively contribute a wealth of knowledge and experience. Together, this cadre of specialists is expected to drive forward the clinical applications of the newly developed nano-PFA 360° Cardiac Catheter, enhancing patient care in the treatment of cardiac arrhythmias.

Burke T. Barrett, President and CEO of Pulse Biosciences, emphasizes the strategic nature of these appointments, highlighting the importance of robust clinical data in transforming the treatment landscape for atrial fibrillation. The integration of such seasoned professionals is set to propel Pulse Biosciences into its next phase of clinical development, ensuring that the company remains at the forefront of advancements in electrophysiology. As the team gears up for pivotal clinical trials and commercial launches, the potential for improved treatment outcomes for patients suffering from AF becomes increasingly promising.

In addition to its leadership enhancements, Pulse Biosciences is progressing on multiple fronts with its nsPFA technology. The company has initiated a pilot program deploying nsPFA Percutaneous Electrode Systems at seven U.S. sites, with commercial availability on the horizon. Furthermore, Pulse is preparing for a pivotal clinical trial aimed at obtaining FDA approval for treating benign thyroid nodules, with preliminary European feasibility study results set to be presented at the American Thyroid Association Conference later this month.

As Pulse Biosciences continues to expand its clinical efforts and regulatory initiatives, the commitment to elevating treatment standards for patients with AF and other conditions remains a core focus. With a strong leadership team in place and innovative technologies on the horizon, Pulse is poised for significant advancements in the field of electrophysiology.